These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21890570)

  • 21. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 23. Elevated International Normalized Ratio in a Patient Taking Warfarin and Mauby: A Case Report.
    Sorbera M; Joseph T; DiGregorio RV
    J Pharm Pract; 2017 Oct; 30(5):567-570. PubMed ID: 27543375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 25. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction.
    Howard-Thompson A; Hurdle AC; Arnold LB; Finch CK; Sands C; Self TH
    Am J Geriatr Pharmacother; 2008 Mar; 6(1):33-6. PubMed ID: 18396247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probable drug interaction between warfarin and hormonal contraceptives.
    Zingone MM; Guirguis AB; Airee A; Cobb D
    Ann Pharmacother; 2009 Dec; 43(12):2096-102. PubMed ID: 19934391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin and warfarin interaction.
    Jones CB; Fugate SE
    Ann Pharmacother; 2002 Oct; 36(10):1554-7. PubMed ID: 12243605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
    Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased INR response secondary to warfarin-flucloxacillin interaction.
    Garg A; Mohammed M
    Ann Pharmacother; 2009 Jul; 43(7):1374-5. PubMed ID: 19584391
    [No Abstract]   [Full Text] [Related]  

  • 31. Interaction potential between cranberry juice and warfarin.
    Pham DQ; Pham AQ
    Am J Health Syst Pharm; 2007 Mar; 64(5):490-4. PubMed ID: 17322161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
    Kim HO; Lee KE; Park HY; Lee NR; Oh BR; Chang BC; Gwak HS
    J Pharm Pharmacol; 2013 Aug; 65(8):1195-203. PubMed ID: 23837587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib.
    Lim S; Houranieh J; Crawford R
    Am J Health Syst Pharm; 2014 Feb; 71(3):200-3. PubMed ID: 24429012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.
    Soon D; Kothare PA; Linnebjerg H; Park S; Yuen E; Mace KF; Wise SD
    J Clin Pharmacol; 2006 Oct; 46(10):1179-87. PubMed ID: 16988207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.